about
Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitorsInterventions for enhancing medication adherenceImmune tolerance induction for treating inhibitors in people with congenital haemophilia A or BAntiviral treatment for chronic hepatitis C in patients with human immunodeficiency virusClotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or BAntiviral therapy for chronic hepatitis C in patients with human immunodeficiency virusClotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or BShared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: Results from the HERO qualitative study.Effectiveness of computerized decision support systems linked to electronic health records: a systematic review and meta-analysisLarge scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more.The current state of adverse event reporting in hemophilia.A critical appraisal of chronic kidney disease mineral and bone disorders clinical practice guidelines using the AGREE II instrument.Authors seldom report the most patient-important outcomes and absolute effect measures in systematic review abstracts.Care models in the management of haemophilia: a systematic reviewNHF-McMaster Guideline on Care Models for Haemophilia Management.First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System.Impact of missing participant data for dichotomous outcomes on pooled effect estimates in systematic reviews: a protocol for a methodological study.Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data.Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor. Patient Data Meta-analysis of rAFH-PFM Post-Authorization Safety Studies.Reporting, handling and assessing the risk of bias associated with missing participant data in systematic reviews: a methodological surveyUse of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol.Individual participant data meta-analyses compared with meta-analyses based on aggregate data.Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo).Measuring the quality of haemophilia care across different settings: a set of performance indicators derived from demographics data.Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis.Seizures, headache and thrombocytopenia: diagnosis and treatment do not always come in a standard sequence.Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies.Thrombosis in Inherited Fibrinogen Disorders.The haemophilia certification system in CanadaAryl hydrocarbon receptor control of a disease tolerance defence pathwayPatient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism.Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review.Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey.Guideline for opioid therapy and chronic noncancer pain.D-dimer testing to determine the duration of anticoagulation therapy.Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysisEnoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery.Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression.Prophylaxis in older Canadian adults with hemophilia A: lessons and more questionsApplied pharmacoeconomics: considerations to drive the choice of a prophylactic antithrombotic regimen.
P50
Q24187069-ED91F8CA-F1E8-4FA3-90B0-929933502328Q24187912-A40024F0-F32C-45CA-BCAD-FAFAE14A8D0EQ24195006-82AB6801-645A-4E72-BDC3-D59E17F00F43Q24240929-ED5D1D1E-453F-40AA-B32F-44C2BC875905Q24243897-557EF4B6-F1B3-4FBB-9300-3063B5EA9CDEQ24246928-BEFCB972-FE77-410D-B6F3-89B7E7CDE275Q24246950-5D856542-D466-4E8C-81CA-4EC33E9DE0ACQ27303108-2BADE0E6-DFF8-460D-A6B8-9B22828479B9Q28249833-5CDDA067-56F9-48E6-BA6B-A5B99FD86ADEQ30234910-D7315349-1E14-4F8A-B817-C79003FCE075Q30239952-29506254-2820-40C7-BE12-789D5F64B1D7Q30241974-96486393-F8C3-40E3-B8B3-299E19F9033BQ30248331-F405FC8E-582C-4C4A-A6CF-2A58637E26A1Q30249304-3C530EFC-005C-451C-8510-0F98E98F8032Q30249305-21326697-1356-4616-8AF5-DFAD14864CD5Q30832356-7E0ACD5C-D59E-4A31-8930-89F9F2BD23B1Q30871934-37EEC830-5CE5-4627-A285-0353E2AACCC8Q30889099-E2E10762-3704-496A-93A4-2E83D5C9C5C2Q30959893-9E2D6190-D0B7-4695-983A-C70ADA24A9DFQ30999735-C2C618E2-D455-43CE-BCCE-DB01E71E7AB1Q31088061-909F3463-F9B9-42DD-ADED-3F76F2D7D9C7Q31126782-75234A9D-2E20-4D91-B0A1-BDA0113265F1Q31147438-F6CFFE64-D76D-4DF0-9CED-4859E0CFCE62Q31147487-E8430F62-9F12-4A21-A028-6A293C1D973BQ33324733-53EC1F62-C0B0-430B-9C99-CA939A010CCAQ33376872-19F903A9-69E7-4E0A-9B1A-F356CA22AF22Q33553076-EB3C78B6-C29F-4370-B1AD-CD7674992CADQ33659450-7168B0C5-9C5B-4F0B-BF2A-58D7593729F4Q33708993-C8643B95-9832-4225-A1FF-C9250EE83D2CQ33901562-7D8906D2-65F2-4343-9952-ECC99105E5DDQ34144428-59632E5B-5FDD-495D-9D86-F7F889D7E954Q34145656-7CD7CA8A-C508-49AC-B6EE-D397971E803BQ34420450-1B83A6D2-7314-4758-AC28-D7377C4EA05BQ34556388-DC597168-81BD-49E9-AF85-4F5C6076AE5BQ34576728-19950BC3-AC26-4BB3-86F0-22A94A4EC66DQ34603112-97978F9B-42C3-4F89-8BE6-239FE098E57DQ34748945-D33F55D7-D884-44E4-9564-92E869678D83Q34784564-00A6FF87-D5B2-459C-94BC-7BC25424E9CEQ35091077-6D4A8BA0-34F8-483A-A416-C6B7869D1288Q35181689-DDE310B5-F32D-4537-8A83-53925056E4E7
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alfonso Iorio
@ast
Alfonso Iorio
@en
Alfonso Iorio
@es
Alfonso Iorio
@nl
type
label
Alfonso Iorio
@ast
Alfonso Iorio
@en
Alfonso Iorio
@es
Alfonso Iorio
@nl
prefLabel
Alfonso Iorio
@ast
Alfonso Iorio
@en
Alfonso Iorio
@es
Alfonso Iorio
@nl
P108
P1053
B-9478-2013
P106
P1153
7006482295
P21
P31
P3829
P3835
alfonso-iorio
P496
0000-0002-3331-8766